NACDS Statement on FDA’s Recommendation to Reschedule Hydrocodone

Published Online: Friday, October 25, 2013
Follow Pharmacy_Times:
PRESS RELEASE

Arlington, Va. - NACDS issued the following statement on October 24 regarding news that the Food and Drug Administration (FDA) is recommending the rescheduling of combination hydrocodone medications from Schedule III to Schedule II:

“Pharmacies have a zero tolerance for prescription drug abuse and a 100-percent commitment to patient care. This proposal is not the best avenue to address abuse, and would negatively impact access to needed medications for those who suffer from chronic pain. In the interest of patient care, we have worked with patient advocacy groups in opposition to this recommendation as we support and advance workable solutions.”

For more information, please see a recent column by NACDS President and CEO Steven C. Anderson, IOM, CAE, titled “Addressing Prescription Drug Abuse and Access Issues – Every Day.”
Related Articles
Pharmacists and their patients can help prevent prescription drug misuse, abuse, and diversion through a new educational tool launched by the Alliance for Balanced Pain Management (AfBPM).
For many pharmacy organizations, the Supreme Court King v. Burwell decision upholding the Affordable Care Act’s tax subsidies fended off potential confusion for patients concerning health insurance.
If a projected 92% past participant return rate is any indication of an event’s value, then success is once again in store for the third annual NACDS Total Store Expo.
Amanda Bright, pharmacy student at Ernest Mario School of Pharmacy at Rutgers University, talks about a panel she helped establish that raises awareness about prescription drug abuse.
Latest Issues
$auto_registration$